EMD Serono appoints Frederick Munschauer VP medical affairs, neurology and immunology

2 April 2015

EMD Serono, the US biopharma subsidiary of Germany’s Merck KGaA (MRK: DE) has appointed Frederick Munschauer as vice president of medical affairs, neurology and immunology.

He will lead the medical affairs activity for clinical, commercial and business development projects and collaborations for Rebif (interferon beta-1a), and the company’s immunology and neurology pipeline.

He joins from Biogen (Nasdaq: BIIB) and brings more than 30 years of knowledge in neurology, with specialism in multiple sclerosis. He also served as head of US medical affairs and head of global medical affairs at Biogen.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK